Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06815029 · ClinicalTrials.gov registry record · Phase 1

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

A Phase 1 study of Recurrent Glioblastoma and Recurrent Astrocytoma, IDH-Mutant, Grade 4, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT06815029 is a Phase 1 study of Recurrent Glioblastoma and Recurrent Astrocytoma, IDH-Mutant, Grade 4 that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 27 participants, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06815029, a Phase 1 study of Recurrent Glioblastoma and Recurrent Astrocytoma, IDH-Mutant, Grade 4, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. When the cells are taken from the patient's own blood, it is known as autologous. Then the gene for special receptors that bind to a certain proteins on the patient's tumor cells are added to the T cells in the laboratory. The special receptors are called CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving TGFβR2KO/IL13Rα2 CAR T cells may be safe, tolerable, and/or effective in treating patients with recurrent or progressive glioblastoma or grade 3 or 4 IDH-mutant astrocytoma.

Conditions Studied

Recurrent Glioblastoma Recurrent Astrocytoma, IDH-Mutant, Grade 4 Recurrent Astrocytoma, IDH-Mutant, Grade 3

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Fludeoxyglucose F-18
  • PROCEDURE Echocardiography
  • BIOLOGICAL Chimeric Antigen Receptor T-Cell Therapy
  • PROCEDURE Intracranial Catheter Placement

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2025-06-17
Est. Completion 2030-10-11
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06815029

The ClinicalTrials.gov registry entry for NCT06815029 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (60% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06815029 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06815029 about?

NCT06815029 is a clinical study titled "Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma". This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent)...

What is the current status of trial NCT06815029?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-06-17. Estimated completion is 2030-10-11.

What conditions does trial NCT06815029 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Astrocytoma, IDH-Mutant, Grade 3.

What interventions are being tested in trial NCT06815029?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Fludeoxyglucose F-18 (OTHER), Echocardiography (PROCEDURE), Chimeric Antigen Receptor T-Cell Therapy (BIOLOGICAL), Intracranial Catheter Placement (PROCEDURE).

Who is sponsoring clinical trial NCT06815029?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06815029 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Glioblastoma

All registered trials for this condition

Recurrent Astrocytoma, IDH-Mutant, Grade 4

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.